{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05918692",
            "orgStudyIdInfo": {
                "id": "COVALENT-103"
            },
            "organization": {
                "fullName": "Biomea Fusion Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 1, Study of BMF-500 in Adults With Acute Leukemia",
            "officialTitle": "A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of BMF-500, an Oral Covalent FLT3 Inhibitor, in Adults With Acute Leukemia",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-phase-study-of-bmf-in-adults-with-acute-leukemia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-26",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-07-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-18",
            "studyFirstSubmitQcDate": "2023-06-23",
            "studyFirstPostDateStruct": {
                "date": "2023-06-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Biomea Fusion Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.",
            "detailedDescription": "A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adult patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and Acute Mixed-Phenotype Leukemia (MPAL) who may or may not be on Antifungals."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Myeloid Leukemia",
                "Acute Lymphoblastic Leukemia",
                "Acute Mixed-Phenotype Leukemia"
            ],
            "keywords": [
                "FLT3",
                "FLT3-ITD",
                "FLT-TKD",
                "AML",
                "ALL",
                "AMPL",
                "FLT3 Wild-Type",
                "MLL-R",
                "NPM1"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Accelerated Titration Design, Followed by Modified 3+3",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 110,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Escalation Phase",
                    "type": "EXPERIMENTAL",
                    "description": "BMF-500 taken twice daily by participants who are not receiving drugs that inhibit CYP3A4 activity or who are receiving necessary azole antifungals that are moderate or strong CYP3A4 inhibitors excluding other moderate or strong CYP3A4 inhibitors.",
                    "interventionNames": [
                        "Drug: BMF-500"
                    ]
                },
                {
                    "label": "Expansion Phase",
                    "type": "EXPERIMENTAL",
                    "description": "BMF-500 taken twice daily by participants who are not receiving drugs that inhibit CYP3A4 activity or who are receiving necessary azole antifungals that are moderate or strong CYP3A4 inhibitors excluding other moderate or strong CYP3A4 inhibitors.",
                    "interventionNames": [
                        "Drug: BMF-500"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BMF-500",
                    "description": "Investigational Product",
                    "armGroupLabels": [
                        "Escalation Phase",
                        "Expansion Phase"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Evaluate the safety and tolerability of BMF-500 monotherapy by incidence of Treatment Emerging Adverse Events (TEAEs).",
                    "description": "Assessed by the NCI CTCAE version 5.0.",
                    "timeFrame": "At the end of each 28 Day cycle for a maximum of 32 cycles"
                },
                {
                    "measure": "Evaluate the safety and tolerability of BMF-500 monotherapy by incidence of Serious Adverse Events (SAEs).",
                    "description": "Assessed by the NCI CTCAE version 5.0.",
                    "timeFrame": "At the end of each 28 Day cycle for a maximum of 32 cycles"
                },
                {
                    "measure": "Determine the recommended Phase 2 Dose (RP2D) of BMF-500.",
                    "description": "Safety, as determined by Dose-Limiting Toxicities (clinically significant Adverse Event) within each dose level assessed NCI CTCAE version 5.0.",
                    "timeFrame": "At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period"
                },
                {
                    "measure": "Determine the recommended Phase 2 Dose (RP2D) of BMF-500.",
                    "description": "Efficacy within each dose level as determined by composite complete remission (CRc).",
                    "timeFrame": "At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period"
                },
                {
                    "measure": "Determine the recommended Phase 2 Dose (RP2D) of BMF-500.",
                    "description": "Pharmacovigilance (PK) at each dose level as determined by the maximum plasma concentration (Cmax).",
                    "timeFrame": "At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period"
                },
                {
                    "measure": "Determine the recommended Phase 2 Dose (RP2D) of BMF-500.",
                    "description": "Pharmacovigilance (PK) at each dose level as determined by area under the plasma concentration from time 0 to last quantifiable concentration (AUClast).",
                    "timeFrame": "At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Determine the pharmacokinetics of BMF-500.",
                    "description": "Maximum plasma concentration (Cmax).",
                    "timeFrame": "At the end of each cycle (each cycle is 28 days in duration) for 7 cycles"
                },
                {
                    "measure": "Determine the pharmacokinetics of BMF-500.",
                    "description": "Area under the plasma concentration from time 0 to last quantifiable concentration (AUClast).",
                    "timeFrame": "At the end of each cycle (each cycle is 28 days in duration) for 7 cycles"
                },
                {
                    "measure": "Assess the effect of food on the PK exposure of BMF-500 in participants receiving BMF-500 (for escalation only).",
                    "description": "Maximum plasma concentration (Cmax).",
                    "timeFrame": "At the end of cycle 1 and 2 (each cycle is 28 days in duration)"
                },
                {
                    "measure": "Assess the effect of food on the PK exposure of BMF-500 in participants receiving BMF-500 (for escalation only).",
                    "description": "Area under the plasma concentration from time 0 to last quantifiable concentration (AUClast).",
                    "timeFrame": "At the end of cycle 1 and 2 (each cycle is 28 days in duration)"
                },
                {
                    "measure": "Evaluate the efficacy of BMF-500",
                    "description": "Composite Complete Remission (CRc).",
                    "timeFrame": "At the end of each cycle (each cycle is 28 days in duration) for a maximum of 32 cycles"
                },
                {
                    "measure": "Assess additional evidence of antitumor activity per investigator assessment as per corresponding response criteria.",
                    "description": "Duration of Response (DOR).",
                    "timeFrame": "At the end of each cycle (each cycle is 28 days in duration) for a maximum of 32 cycles"
                },
                {
                    "measure": "Evaluate the efficacy of BMF-500",
                    "description": "Overall Reasons Rate (ORR).",
                    "timeFrame": "At the end of each cycle (each cycle is 28 days in duration) for a maximum of 32 cycles"
                },
                {
                    "measure": "Assess additional evidence of antitumor activity per investigator assessment as per corresponding response criteria.",
                    "description": "Relapse free survival (RFS).",
                    "timeFrame": "At the end of each cycle (each cycle is 28 days in duration) for a maximum of 32 cycles"
                },
                {
                    "measure": "Assess additional evidence of antitumor activity per investigator assessment as per corresponding response criteria.",
                    "description": "Overall Survival (OS).",
                    "timeFrame": "At the end of each cycle (each cycle is 28 days in duration) for a maximum of 32 cycles"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Age \u2265 18 years.\n* Individuals with histologically or pathologically confirmed diagnosis of relapsed or refractory AML, ALL, or MPAL with documented FLT3 mutation, and/or Individuals with histologically or pathologically confirmed diagnosis of their malignancy with wild-type FLT3 (including those with MLL1-R and NPM1 mutations).\n* ECOG performance status of 0-2.\n* Adequate liver and renal function\n* Adhere to the CYP3A4 inhibitor concomitant therapy use requirements, as follows:\n* Arm A: Participants must not have received a moderate or strong CYP3A4 inhibitor for at least 7 days prior to enrollment and are not anticipated to require such agents in the near term (for at least 4 weeks).\n* Arm B: Participants must have received a necessary azole antifungal(s) that is a moderate or strong CYP3A4 inhibitor (excluding other moderate or strong CYP3A4 inhibitor\\[s\\]) for at least 7 days prior to enrollment and be able to continue such azole antifungal(s) while on BMF-500 treatment for at least 4 weeks.\n\nKey Exclusion Criteria:\n\n* Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension or arrhythmia, history of cerebrovascular accident including transient ischemic attack within 6 months prior to the first dose of the trial intervention.\n* WBC count \\>50,000/\u00b5L (uncontrollable with cytoreductive therapy).\n* Women who are pregnant or lactating or plan to become pregnant.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Mona Vimal",
                    "role": "CONTACT",
                    "phone": "1-844-245-0490",
                    "email": "clinicaltrials@biomeafusion.com"
                },
                {
                    "name": "Alex Cacovean, MD",
                    "role": "CONTACT",
                    "phone": "1-844-245-0490",
                    "email": "clinicaltrials@biomeafusion.com"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Phoenix",
                    "state": "Arizona",
                    "zip": "85054",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.44838,
                        "lon": -112.07404
                    }
                },
                {
                    "facility": "City of Hope National Medical Center",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "UCLA Department of Medicine",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California, Davis",
                    "status": "RECRUITING",
                    "city": "Sacramento",
                    "state": "California",
                    "zip": "95817",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.58157,
                        "lon": -121.4944
                    }
                },
                {
                    "facility": "University of California, San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Colorado Blood Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Mayo Clinic",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32224",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "Winship Cancer Institute, Emory University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Northwestern Memorial Hospital",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "University of Chicago Duchossois Center for Advanced Medicine (DCAM)",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60637",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "University of Kentucky - Markey Cancer Center",
                    "status": "RECRUITING",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40536",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                },
                {
                    "facility": "Mayo Clinic",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55902",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "John Theurer Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "Montefiore Hospital - Moses Campus - BRANY - PPDs",
                    "status": "RECRUITING",
                    "city": "Bronx",
                    "state": "New York",
                    "zip": "10467",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.84985,
                        "lon": -73.86641
                    }
                },
                {
                    "facility": "Roswell Park Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "Northwell Health Cancer Institute",
                    "status": "RECRUITING",
                    "city": "New Hyde Park",
                    "state": "New York",
                    "zip": "11042",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.7351,
                        "lon": -73.68791
                    }
                },
                {
                    "facility": "East Carolina University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Greenville",
                    "state": "North Carolina",
                    "zip": "27858",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.61266,
                        "lon": -77.36635
                    }
                },
                {
                    "facility": "Cleveland Clinic Hospital",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "University of Oklahoma - Stephenson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Texas Oncology-PA USOR",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75251",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Gainesville",
                    "state": "Virginia",
                    "zip": "20155",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.79567,
                        "lon": -77.61388
                    }
                },
                {
                    "facility": "Fred Hutchinson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000054198",
                    "term": "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000007945",
                    "term": "Leukemia, Lymphoid"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M27585",
                    "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10951",
                    "name": "Leukemia, Lymphoid",
                    "relevance": "LOW"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "relevance": "LOW"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "relevance": "LOW"
                },
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T175",
                    "name": "Acute Lymphoblastic Leukemia",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3533",
                    "name": "Lymphoblastic Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "asFound": "Acute",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M6252",
                    "name": "Clotrimazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M11796",
                    "name": "Miconazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M4254",
                    "name": "Antifungal Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}